Interaction between the unphosphorylated receptor with high affinity for IgE and Lyn kinase.
Chinese hamster ovary fibroblasts previously transfected with the high affinity receptor for IgE (FcepsilonRI) were further transfected with the alpha subunit of the receptor for interleukin 2 (Tac) or with chimeric constructs in which the cytoplasmic domain of Tac was replaced with the C-terminal cytoplasmic domain of either the beta subunit or the gamma subunit of FcepsilonRI. Whereas native Tac failed to affect the aggregation-induced phosphorylation of FcepsilonRI, both chimeric constructs substantially inhibited this reaction. Alternatively, the FcepsilonRI-bearing fibroblasts were transfected with two chimeric constructs in which the cytoplasmic domain of Tac was replaced with a modified short form of Lyn kinase. The Lyn in both of the chimeric constructs had been mutated to remove the sites that are normally myristoylated and palmitoylated, respectively; one of the constructs had in addition been altered to be catalytically inactive. The catalytically active construct enhanced, and the inactive construct inhibited, aggregation-induced phosphorylation of the receptors. All of the chimeric constructs were largely distributed outside the detergent resistant microdomains, and whereas aggregation caused them to move to the domains in part, their aggregation was neither necessary nor enhanced their effects. These results and others indicate that the receptor and Lyn interact through protein-protein interactions that neither are dependent upon either the post-translational modification of the kinase with lipid moieties nor result exclusively from their co-localization in specialized membrane domains.
Vonakis
B M
BM
Section on Chemical Immunology, Arthritis and Rheumatism Branch, NIAMS, National Institutes of Health, Bethesda, Maryland 20892-1820, USA.
Haleem-Smith
H
H
Benjamin
P
P
Metzger
H
H
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D016466:CHO Cells; D006224:Cricetinae; D005347:Fibroblasts / Q000166:cytology / Q000502:physiology; D007073:Immunoglobulin E / Q000378:metabolism*; D007700:Kinetics; D019814:Myristic Acid / Q000378:metabolism; D009856:Oncogene Proteins, Viral / Q000378:metabolism; D019308:Palmitic Acid / Q000378:metabolism; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D021122:Protein Subunits; D051381:Rats; D017455:Receptors, IgE / Q000378:metabolism*; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D014162:Transfection; D019061:src-Family Kinases / Q000378:metabolism*
D009856:Oncogene Proteins, Viral; D021122:Protein Subunits; D017455:Receptors, IgE; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D019814:Myristic Acid; D019308:Palmitic Acid; D007073:Immunoglobulin E; D000255:Adenosine Triphosphate; C060902:lyn protein-tyrosine kinase; D019061:src-Family Kinases